Mr. Maki has over 20 years of industry
experience and has been founding investor and/or board member of eleven life science
companies. In addition, three of Mr. Maki’s portfolio companies had successful IPOs
and grew to a combined market capitalization exceeding $1.4 billion dollars. Mr. Maki
currently serves on the boards of 3DMatrix, a bone regeneration device company, Addition
Technology, an ophthalmic device company and Vicus Therapeutics. Mr. Maki also serves
on the Board of Trustees of BIO NJ.
Newell F. Bascomb, Chief Operating Officer
Previously, Venture Partner, Technology
Directors, Inc., 2004-2005; VP Business Development, Sunol Molecular Corporation,
2002-2004; President, CEO and Founder, Xios Biosciences, 2001-2002; President and
Co-Founder, Icon Genetics, 1998-2001; Direct, American Home Products, 1991-1998;
Manager, EniChem Americas, 1987-1991; Research Scientist, E.I. DuPont de Nemours,
1985-1987; B.S., Juniata College; M.S., Virginia Tech; Ph.D., University of Florida, 1985.
Navaneetha K. Rao, Vice President Clinical Research and Development
Previously, Assistant Vice President,
Clinical Research and Development, Reliance Life Sciences (India) and Head, Reliance
Clinical Research Services,2004-2006, 2005-2006; Associate Director, Clinical
Development, Cato Research Limited, 1998-2004; Post Doctoral Research Fellow,
Brigham and Women’s Hospital, Harvard Medical School, 1994-1998; B.Sc., NDRI,
India; M.S., Virginia Tech; Sc.D., Harvard University, 1994.
Fredric S. Young, Chief Scientist
Previously, Chief Scientist and Co-Founder,
Chroma Group, 1994-2005; President, Young Consulting 1984-1993; Research Scientist,
Genentech 1980-1984; Research Fellow, NIH, 1977-1980, B.S., Penn State; Ph.D.,
University of Michigan, 1977.
Dr. Young first described the core
elements of Vicus’ platform technology in his PhD thesis, which outlined a theoretical
systems biology framework based on principles of complexity theory. In 1988, Dr. Young
collaborated with Dr. Per Bak at Brookhaven National Laboratory and extended the systems
biology framework to incorporate principles of self-organized criticality. Since 1998,
Dr. Young’s framework has been used to build a highly effective drug discovery and
development technology. His technology wass recently applied to discover the novel
combination product candidates in Vicus’ cancer cachexia program.
Consultants
Richard Guarino, MD
– Medical Affairs (US). Oxford Pharmaceutical Services. Previously with Sandoz, Revlon
Nirupa Bareja, Ph.D
, Country Manager (India). Previously with Biocon Limited.
Shehnaz Vakharia, M.S.
, Quality Assurance, India (India). Previously with Trainor and Partners, CliniRx, Pfizer.
John O’Malley, MBA
- Finance (US), Technology Directors, Inc. Previously with Audax Group, Bain Capital,
Bain & Company.
